Chronically activated microglia in <scp>ALS</scp> gradually lose their immune functions and develop unconventional proteome

Barreto‐Núñez, Romina; Béland, Louis‐Charles; Boutej, Hejer; Picher‐Martel, Vincent; Dupré, Nicolas; Barbeito, Luis; Kriz, Jasna

doi:10.1002/glia.24531

Cited by 3 publications

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike age-matched control mice, BV treatment at a particular stage of ALS development increases motor function and longevity in SOD1G93A mutant mice. This might be due to blocking active microglia, as shown in mouse models of ALS ( Barreto-Núñez et al, 2024 ). The research found that BVA at ST36 reduces inflammation in neurons in the spinal cord of ALS animals, including TLR4, CD14, and TNF-α ( Cai et al, 2015 ).…”

Section: Medical Applicationsmentioning

confidence: 99%

Harnessing the power of bee venom for therapeutic and regenerative medical applications: an updated review

Sadek,

Shib,

Taher

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Honeybees have been helpful insects since ancient centuries, and this benefit is not limited to being a honey producer only. After the bee stings a person, pain, and swelling occur in this place, due to the effects of bee venom (BV). This is not a poison in the total sense of the word because it has many benefits, and this is due to its composition being rich in proteins, peptides, enzymes, and other types of molecules in low concentrations that show promise in the treatment of numerous diseases and conditions. BV has also demonstrated positive effects against various cancers, antimicrobial activity, and wound healing versus the human immunodeficiency virus (HIV). Even though topical BV therapy is used to varying degrees among countries, localized swelling or itching are common side effects that may occur in some patients. This review provides an in-depth analysis of the complex chemical composition of BV, highlighting the diverse range of bioactive compounds and their therapeutic applications, which extend beyond the well-known anti-inflammatory and pain-relieving effects, showcasing the versatility of BV in modern medicine. A specific search strategy was followed across various databases; Web of sciences, Scopus, Medline, and Google Scholar including in vitro and in vivo clinical studies.to outline an overview of BV composition, methods to use, preparation requirements, and Individual consumption contraindications. Furthermore, this review addresses safety concerns and emerging approaches, such as the use of nanoparticles, to mitigate adverse effects, demonstrating a balanced and holistic perspective. Importantly, the review also incorporates historical context and traditional uses, as well as a unique focus on veterinary applications, setting it apart from previous works and providing a valuable resource for researchers and practitioners in the field.

show abstract

Section: Medical Applicationsmentioning

confidence: 99%

Harnessing the power of bee venom for therapeutic and regenerative medical applications: an updated review

Sadek,

Shib,

Taher

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Neuroinflammation and glycosylation-related cerebrospinal fluid proteins for predicting functional decline in amyotrophic lateral sclerosis: a proteomic study

Nakamura,

Fujita,

Suzuki

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

BackgroundThe rate of disease progression varies widely among patients with amyotrophic lateral sclerosis (ALS). Prognostic assessment using biomarkers is highly anticipated to improve clinical trial design. We aimed to explore the cerebrospinal fluid (CSF) for prognostic biomarkers to predict future functional decline in patients with ALS.MethodsWe collected CSF samples from 64 patients with ALS and 25 disease controls. The prospective progression rate was calculated using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) at CSF collection and in 6 months. The ALS patients were classified into slow, intermediate, and fast progression groups. We performed comprehensive proteomic analyses of the CSF samples. Factors with significant changes between slow and fast progression groups were investigated via receiver operating characteristic curve analyses. Moreover, the correlation of the CSF factors with progression rate was evaluated by multiple regression analyses.ResultsIn total, 26 proteins changed significantly (p < 0.05 and q < 0.10), with levels varying within a large dynamic range (fold change of >1.5 or < 0.5). A receiver operating characteristic curve analyses showed that the following proteins showed high discrimination power between slow and fast progression groups: glycoprotein non-metastatic melanoma protein B (GPNMB; area under the curve [AUC], 0.88), glial fibrillary acidic protein (AUC, 0.81), glypican-1 (GPC1; AUC, 0.79), alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (AUC, 0.74), and chitinase-3-like protein 2 (CHI3L2; AUC, 0.73). Of these, GPNMB, GPC1, and CHI3L2 were significantly correlated to prognostic progression rate.ConclusionThis study demonstrated that CSF levels of neuroinflammation and glycosylation-related proteins were significantly correlated with prospective progression rates in patients with ALS. These proteins could be useful prognostic biomarkers for ALS.

show abstract

Myeloid antigen-presenting cells in neurodegenerative diseases: a focus on classical and non-classical MHC molecules

Afify,

Lipsius,

Wyatt-Johnson

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

In recent years, increasing evidence has highlighted the critical role of myeloid cells, specifically those that present antigen (APCs) in health and disease. These shape the progression and development of neurodegenerative disorders, where considerable interplay between the immune system and neurons influences the course of disease pathogenesis. Antigen-presenting myeloid cells display different classes of major histocompatibility complex (MHC) and MHC-like proteins on their surface for presenting various types of antigens to a wide variety of T cells. While most studies focus on the role of myeloid MHC class I and II molecules in health and disease, there is still much that remains unknown about non-polymorphic MHC-like molecules such as CD1d and MR1. Thus, in this review, we will summarize the recent findings regarding the contributions of both classical and non-classical MHC molecules, particularly on myeloid microglial APCs, in neurodegenerative diseases. This will offer a better understanding of altered mechanisms that may pave the way for the development of novel therapeutic strategies targeting immune cell-MHC interactions, to mitigate neurodegeneration and its associated pathology.

show abstract

Chronically activated microglia in ALS gradually lose their immune functions and develop unconventional proteome

Cited by 3 publications

References 61 publications

Harnessing the power of bee venom for therapeutic and regenerative medical applications: an updated review

Harnessing the power of bee venom for therapeutic and regenerative medical applications: an updated review

Neuroinflammation and glycosylation-related cerebrospinal fluid proteins for predicting functional decline in amyotrophic lateral sclerosis: a proteomic study

Myeloid antigen-presenting cells in neurodegenerative diseases: a focus on classical and non-classical MHC molecules

Contact Info

Product

Resources

About